Breakthrough Therapy Awarded to a Drug For RET-Altered Thyroid and Non-Small Cell Lung Cancers
The United States FDA has awarded Breakthrough Therapy Designation to a drug called LOXO-292 for the treatment of RET-altered non-small cell lung cancer and thyroid cancer, in patients who meet…